Please login to the form below

Not currently logged in
Email:
Password:

The Sudler London Award for Excellence in Mature Brand Revitalisation

Sponsored by

Finalist

Making ERBITUX Matter: Born Fighters Campaign

Merck Serono in association with WCG


Summary of work

Merck Serono UK wanted to revitalise the perception of its personalised medicine ERBITUX to physicians treating patients with two types of cancer. ERBITUX was originally approved by the EMA in 2004 based on the pivotal CRYSTAL study results for colorectal cancer, and 2006 based on the pivotal BONNER study results for head and neck cancer. 

Seven years later, these studies are still the primary source of clinical evidence used to promote the use of ERBITUX in colorectal cancer and head and neck cancer. 

Because the colorectal indication requires the use of a biomarker and the head and neck cancer condition does not, the competition focused on convincing physicians it was the “easier” choice and positioned biomarker testing as a burden rather than a tool to guide treatment decisions which was inconsistently applied depending on indication. 

The creative approach across sales materials needed to be informative, compelling and consistent – while allowing for different indications – to facilitate physician dialogue beyond the traditional “data drone”. The result was “Born Fighters” – who represent all patients who deserve a fighting chance to defend their lives against cancer. 

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics